메뉴 건너뛰기




Volumn 139, Issue 7, 2013, Pages 1179-1187

Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma

Author keywords

Fluorescence in situ hybridization; Hepatocellular carcinoma; Mcl 1; pERK; Prognosis; Sorafenib

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN MCL 1; SCATTER FACTOR RECEPTOR; SORAFENIB;

EID: 84879228193     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1429-x     Document Type: Article
Times cited : (27)

References (36)
  • 4
    • 10044285749 scopus 로고    scopus 로고
    • High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma
    • DOI 10.1016/j.humpath.2004.06.012, PII S004681770400365X
    • Chan KL, Guan XY, Ng IO (2004) High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 35:1324-1331 (Pubitemid 39601571)
    • (2004) Human Pathology , vol.35 , Issue.11 , pp. 1324-1331
    • Chan, K.-L.1    Guan, X.-Y.2    Ng, I.O.-L.3
  • 5
    • 0034786019 scopus 로고    scopus 로고
    • L sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis
    • DOI 10.1016/S1097-2765(01)00320-3
    • Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8:705-711 (Pubitemid 32946946)
    • (2001) Molecular Cell , vol.8 , Issue.3 , pp. 705-711
    • Cheng, E.H.-Y.1    Wei, M.C.2    Weiler, S.3    Flavell, R.A.4    Mak, T.W.5    Lindsten, T.6    Korsmeyer, S.J.7
  • 8
    • 3142683869 scopus 로고    scopus 로고
    • MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol
    • DOI 10.1038/sj.onc.1207692
    • Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23:5301-5315 (Pubitemid 39005806)
    • (2004) Oncogene , vol.23 , Issue.31 , pp. 5301-5315
    • Domina, A.M.1    Vrana, J.A.2    Gregory, M.A.3    Hann, S.R.4    Craig, R.W.5
  • 13
    • 61549103137 scopus 로고    scopus 로고
    • Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib
    • 19188183 10.1158/1078-0432.CCR-08-2280 1:CAS:528:DC%2BD1MXht1Ons78%3D
    • Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM (2009) Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res 15:1076-1085
    • (2009) Clin Cancer Res , vol.15 , pp. 1076-1085
    • Jilaveanu, L.1    Zito, C.2    Lee, S.J.3    Nathanson, K.L.4    Camp, R.L.5    Rimm, D.L.6    Flaherty, K.T.7    Kluger, H.M.8
  • 14
    • 33745220780 scopus 로고    scopus 로고
    • Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
    • 16710476 10.1172/JCI27236 1:CAS:528:DC%2BD28XlsFWruro%3D
    • Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582-1595
    • (2006) J Clin Invest , vol.116 , pp. 1582-1595
    • Kaposi-Novak, P.1    Lee, J.S.2    Gòmez-Quiroz, L.3    Coulouarn, C.4    Factor, V.M.5    Thorgeirsson, S.S.6
  • 18
    • 0029043811 scopus 로고
    • Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo
    • 7778670 1:CAS:528:DyaK2MXms1SkurY%3D
    • Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed JC (1995) Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 146:1309-1319
    • (1995) Am J Pathol , vol.146 , pp. 1309-1319
    • Krajewski, S.1    Bodrug, S.2    Krajewska, M.3    Shabaik, A.4    Gascoyne, R.5    Berean, K.6    Reed, J.C.7
  • 19
    • 33846212284 scopus 로고    scopus 로고
    • Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    • DOI 10.1158/0008-5472.CAN-06-1377
    • Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858 (Pubitemid 46094197)
    • (2006) Cancer Research , vol.66 , Issue.24 , pp. 11851-11858
    • Liu, L.1    Cao, Y.2    Chen, C.3    Zhang, X.4    McNabola, A.5    Wilkie, D.6    Wilhelm, S.7    Lynch, M.8    Carter, C.9
  • 21
    • 0024429682 scopus 로고
    • Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: Analysis of 606 patients
    • Nomura F, Ohnishi K, Tanabe Y (1989) Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 64:1700-1707 (Pubitemid 19251142)
    • (1989) Cancer , vol.64 , Issue.8 , pp. 1700-1707
    • Nomura, F.1    Ohnishi, K.2    Tanabe, Y.3
  • 22
    • 84870511276 scopus 로고    scopus 로고
    • Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer
    • Abstract 4005
    • Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC, Jiang Y, Dubey S, Loh E (2012) Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30(Suppl):Abstract 4005
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Oliner, K.S.1    Tang, R.2    Anderson, A.3    Lan, Y.4    Iveson, T.5    Donehower, R.C.6    Jiang, Y.7    Dubey, S.8    Loh, E.9
  • 23
    • 84871623647 scopus 로고    scopus 로고
    • Delving deeper: MCL-1's contributions to normal and cancer biology
    • 23026029 10.1016/j.tcb.2012.08.011 1:CAS:528:DC%2BC3sXhsVGmsQ%3D%3D
    • Perciavalle RM, Opferman JT (2013) Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol 23:22-29
    • (2013) Trends Cell Biol , vol.23 , pp. 22-29
    • Perciavalle, R.M.1    Opferman, J.T.2
  • 28
    • 36549013178 scopus 로고    scopus 로고
    • Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
    • DOI 10.1016/j.jhep.2007.08.018, PII S0168827807005661
    • Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA (2008) Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48:83-90 (Pubitemid 350191996)
    • (2008) Journal of Hepatology , vol.48 , Issue.1 , pp. 83-90
    • Schmitz, K.J.1    Wohlschlaeger, J.2    Lang, H.3    Sotiropoulos, G.C.4    Malago, M.5    Steveling, K.6    Reis, H.7    Cicinnati, V.R.8    Schmid, K.W.9    Baba, H.A.10
  • 30
    • 0029945320 scopus 로고    scopus 로고
    • Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival
    • DOI 10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0. CO;2-M
    • Stuart KE, Anand AJ, Jenkins RL (1996) Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 77:2217-2222 (Pubitemid 26162412)
    • (1996) Cancer , vol.77 , Issue.11 , pp. 2217-2222
    • Stuart, K.E.1    Anand, A.J.2    Jenkins, R.L.3
  • 31
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6    Verweij, J.7    Van Glabbeke, M.8    Van Oosterom, A.T.9    Christian, M.C.10    Gwyther, S.G.11
  • 32
    • 0030951358 scopus 로고    scopus 로고
    • Expression of hepatocyte growth factor and its receptor c-met proto- oncogene in hepatocellular carcinoma
    • DOI 10.1002/hep.510250413
    • Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E (1997) Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology 25:862-866 (Pubitemid 27157127)
    • (1997) Hepatology , vol.25 , Issue.4 , pp. 862-866
    • Ueki, T.1    Fujimoto, J.2    Suzuki, T.3    Yamamoto, H.4    Okamoto, E.5
  • 33
    • 84872549428 scopus 로고    scopus 로고
    • Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)
    • Abstract 4007
    • Verslype C, Cohn AL, Kelley RK, Yang TS, Su WC, Ramies DA, Lee Y, Shen X, Van Cutsem E (2012) Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30(Suppl):Abstract 4007
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Verslype, C.1    Cohn, A.L.2    Kelley, R.K.3    Yang, T.S.4    Su, W.C.5    Ramies, D.A.6    Lee, Y.7    Shen, X.8    Van Cutsem, E.9
  • 34
    • 77950602604 scopus 로고    scopus 로고
    • Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma
    • 20041405 1:CAS:528:DC%2BC3cXks1Sqsro%3D
    • Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM (2010) Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51:836-845
    • (2010) Hepatology , vol.51 , pp. 836-845
    • Xiong, Y.1    Fang, J.H.2    Yun, J.P.3    Yang, J.4    Zhang, Y.5    Jia, W.H.6    Zhuang, S.M.7
  • 35
    • 27144502652 scopus 로고    scopus 로고
    • The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006
    • DOI 10.1038/sj.onc.1208841, PII 1208841
    • Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA (2005) The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24:6861-6869 (Pubitemid 41509409)
    • (2005) Oncogene , vol.24 , Issue.46 , pp. 6861-6869
    • Yu, C.1    Bruzek, L.M.2    Xue, W.M.3    Gores, G.J.4    Carter, C.A.5    Kaufmann, S.H.6    Adjei, A.A.7
  • 36
    • 70049099306 scopus 로고    scopus 로고
    • Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: Evidence from an in vitro study
    • 19698189 10.1186/1741-7015-7-41
    • Zhang Z, Zhou X, Shen H, Wang D, Wang Y (2009) Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 7:41
    • (2009) BMC Med , vol.7 , pp. 41
    • Zhang, Z.1    Zhou, X.2    Shen, H.3    Wang, D.4    Wang, Y.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.